RELENZA
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $2,258 | 1 | 1 |
| 2020 | $1,492 | 2 | 1 |
| 2019 | $300.00 | 1 | 0 |
| 2017 | $21,503 | 11 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $21,803 | 12 | 85.3% |
| Consulting Fee | $3,750 | 3 | 14.7% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase III international, randomized, doubleblind, double dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of oral oseltamivir twice daily in the treatment of hospitalized adults a | GlaxoSmithKline, LLC. | $18,414 | 0 |
| ZANAMIVIR AQUEOUS SOLUTION FOR COMPASSIONATE USE | GlaxoSmithKline, LLC. | $2,090 | 0 |
| An open label, multi center, single arm study to evaluate the safety and tolerability of intravenous zanamivir in the treatment of hospitalized adult, adolescent and pediatric subjects with confirmed influenza infection | GlaxoSmithKline, LLC. | $630.00 | 0 |
| A PHASE III INTERNATIONAL, RANDOMIZED, DOUBLEBLIND, DOUBLE-DUMMY STUDY | GlaxoSmithKline, LLC. | $300.00 | 0 |
Top Doctors Receiving Payments for RELENZA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Worcester, MA | $21,803 | 12 |
| , MD | Pediatric Infectious Diseases | Durham, NC | $3,750 | 3 |
Manufacturing Companies
- GlaxoSmithKline, LLC. $25,553
Product Information
- Type Drug
- Total Payments $25,553
- Total Doctors 1
- Transactions 15
About RELENZA
RELENZA is a drug associated with $25,553 in payments to 1 healthcare providers, recorded across 15 transactions in the CMS Open Payments database. The primary manufacturer is GlaxoSmithKline, LLC..
Payment data is available from 2017 to 2023. In 2023, $2,258 was paid across 1 transactions to 1 doctors.
The most common payment nature for RELENZA is "Unspecified" ($21,803, 85.3% of total).
RELENZA is associated with 4 research studies, including "A Phase III international, randomized, doubleblind, double dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of oral oseltamivir twice daily in the treatment of hospitalized adults a" ($18,414).